13 May 2008 09:07
Director's Dealings
PuriCore Director Acquires Shares in the Company
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 12 May 2008-PuriCore (LSE: PURI), the life sciences company focused on the control of infectious pathogens with its novel, safe antimicrobial technology, today announces that today the following Director purchased shares in the Company, as set out below:
| Name | Number of shares purchased | Purchase Price of shares | Total number of shares held | % of issued share capital |
| Michael Sapountzoglou | 10,000 | 25.50p | 85,000 | 0.05 |
Enquiries:
| Ben Brewerton | Greg Bosch, CEO |
| Susan Quigley | Keith A. Goldan, CFO |
| Financial Dynamics | PuriCore |
| +44 (0) 20 7831 3113 | +1 484 321 2700 |
About PuriCore
PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore's technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, wound therapy, and hospitality. The Company's proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. Deploying hypochlorous acid solutions as soaks, sprays, mists, and in other forms, PuriCore's technology is designed to limit the spread of infectious disease, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, Avian Influenza, HIV, Polio Virus, Helicobater pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.